Previous 10 | Next 10 |
Company announcement – No. 1 / 2024 Zealand Pharma announces directed issue and private placement for gross proceeds of DKK 1.45 billion NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION IN WHOLE OR IN PART IN OR INTO THE UNITED STATES, AUSTRALIA, CANADA, JAPAN OR SOUTH AFRICA, EX...
Press Release – No. 1 / 2024 Zealand Pharma to participate in the Goldman Sachs Healthcare C-Suite Unscripted Conference on January 4th Copenhagen, Denmark, January 2, 2024 – Zealand Pharma A/S (CVR-no. 20045078), a biotechnology company focused on the disc...
Company announcement – No. 45 / 2023 U.S. Food and Drug Administration issues Complete Response Letter for dasiglucagon in congenital hyperinsulinism for up to three weeks of dosing due to inspection findings at third-party manufacturing facility The CRL is related to defic...
Press release – No. 18 / 2023 Zealand Pharma submits New Drug Application to the US FDA for glepaglutide in short bowel syndrome Copenhagen, Denmark, December 22, 2023 – Zealand Pharma A/S (Nasdaq: ZEAL) (“Zealand”) (CVR-no. 20045078), a biotech...
Press release No. 17 / 2023 Zealand Pharma enters into EUR 90 million finance agreement with the European Investment Bank Copenhagen, Denmark, December 22 , 2023 – Zealand Pharma A/S (Nasdaq: ZEAL) (“Zealand”) (CVR-no. 20045078) a biotechnology com...
Press release – No. 16 / 2023 Zealand Pharma to highlight obesity pipeline at R&D Event on December 5 Event to be hosted by company management and feature key external scientific and clinical experts Copenhagen, Denmark, December 4, 2023 – Zealand...
Company announcement – No. 40 / 2023 Zealand Pharma appoints Enrique Conterno and Elaine Sullivan as board observers Copenhagen, Denmark, November 30, 2023 – a Zealand Pharma A/S (CVR-no. 20045078), a biotechnology company focused on the discovery and devel...
2023-11-10 12:15:26 ET Zealand Pharma A/S (ZEAL) Q3 2023 Earnings Conference Call November 09, 2023 08:00 AM ET Company Participants Anna Krassowska - Vice President-Investor Relations Adam Steensberg - President & Chief Executive Officer David Kendall - Chie...
Company announcement - No. 38 / 2023 Zealand Pharma Announces Financial Results for the First Nine Months of 2023 Strong progress across obesity pipeline, first PDUFA date for dasiglucagon in CHI in 2023 and solid financial position Boehringer Ingelheim advances GCGR/GLP-1R ...
Press release – No. 15 / 2023 Zealand Pharma to participate in the Jefferies London Healthcare Conference in November 2023 Copenhagen, Denmark, November 7, 2023 – Zealand Pharma A/S (Nasdaq: ZEAL) (CVR-no. 20045078), a biotechnology company focused on the discovery a...
News, Short Squeeze, Breakout and More Instantly...
Company announcement – No. 35 / 2024 Zealand Pharma announces completion of an upsized equity offering of 8.35 million new ordinary shares raising gross proceeds of USD 1 billion / DKK 7 billion NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION IN WHOLE OR IN PART IN OR INTO THE U...
Company announcement – No. 34 / 2024 Zealand Pharma announces upsizing of previously announced equity offering from approximately USD 900 million / DKK 6.257 billion to USD 1 billion / DKK 7 billion NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION IN WHOLE OR IN PART IN OR INTO T...
Company announcement – No. 33 / 2024 Zealand Pharma launches equity offering of new shares raising gross proceeds of approximately USD 900 million / DKK 6.257 billion NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION IN WHOLE OR IN PART IN OR INTO THE UNITED STATES, AUSTRALIA, CAN...